Clinical Trials Logo

Filter by:
NCT ID: NCT00323661 Completed - Clinical trials for Cardiac Pacing, Artificial

Closed Loop Stimulation, Cognitive Performance, and Quality of Life in Pacemaker Patients

COGNITION
Start date: May 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the influence of accelerometer-based rate adaptation and Closed Loop Stimulation on cognitive performance and quality of life in pacemaker patients.

NCT ID: NCT00322621 Completed - Clinical trials for Diabetic Neuropathies

Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

Start date: April 2006
Phase: Phase 4
Study type: Interventional

To determine if duloxetine 60 mg once daily can work up to 6 months in treating pain from Diabetic Neuropathy.

NCT ID: NCT00320489 Completed - Schizophrenia Clinical Trials

Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

Start date: April 2006
Phase: Phase 3
Study type: Interventional

To compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine.

NCT ID: NCT00319046 Completed - Clinical trials for Gaucher Disease Type 1

Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease

Start date: February 1, 2006
Phase: Phase 3
Study type: Interventional

Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are required to establish the long term efficacy, safety and tolerability of miglustat in maintaining diseases stability after a switch from ERT.

NCT ID: NCT00318422 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

LEAD-1
Start date: May 2006
Phase: Phase 3
Study type: Interventional

This trial is conducted globally (the United States of America excepted). This trial is designed to show the effect of treatment with liraglutide when added to existing glimepiride therapy and to compare this to both glimepiride monotherapy and to rosiglitazone as add-on therapy to glimepiride.

NCT ID: NCT00317980 Completed - Clinical trials for Cutaneous Leishmaniasis

Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis

Lowdosesb
Start date: February 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether low-dose pentavalent antimony is equally effective when compared to the standard-dose regimen in patients with cutaneous leishmaniasis. The study will be done in a field clinic in the state of Bahia, Brazil.

NCT ID: NCT00317876 Completed - Fanconi Anemia Clinical Trials

Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia

Start date: June 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide, before a donor bone marrow transplant helps stop the growth of abnormal cells. It also stops the patient's immune system from rejecting the donor's bone marrow. The donated bone marrow stem cells may replace the patient's immune system and help destroy any remaining abnormal cells. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and methotrexate before or after transplant may stop this from happening. PURPOSE: This phase I trial is studying the side effects and best dose of cyclophosphamide in treating patients who are undergoing a donor bone marrow transplant for Fanconi's anemia.

NCT ID: NCT00317395 Completed - Coronary Disease Clinical Trials

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

SEPIA-ACS1
Start date: June 2006
Phase: Phase 2
Study type: Interventional

Primary objective: To demonstrate the clinical efficacy of otamixaban (dose effect via 5 intravenous [IV] regimens) in patients with moderate-to-high-risk non-ST elevation acute coronary syndromes (ACS) and planned early invasive strategy. Secondary objectives: To evaluate safety and assess pharmacokinetics (PK) and pharmacodynamics (PD).

NCT ID: NCT00317330 Completed - Tuberculosis Clinical Trials

A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis

Start date: December 2004
Phase: Phase 3
Study type: Interventional

This study will test the effectiveness of two different tuberculosis (TB) prevention strategies, DOTS or DOTS-A. DOTS is the current prevention strategy for TB. DOTS-A is an enhanced prevention strategy that will screen household members of individuals diagnosed with active TB and will provide enhanced treatment as needed. The study will be conducted in 8 communities located in Rio de Janeiro. Study participants will include 6400 males and females of all ages, including active TB patients and their household contacts. Patients with TB identified for treatment at the Health Clinics of 8 urban communities will be eligible. The communities will be assigned to 1 of the 2 prevention strategies, DOTS or DOTS-A. After 4 years, the information gathered during the study will be used to determine the incidence of TB in these communities to see which prevention strategy was more effective in decreasing TB.

NCT ID: NCT00317005 Completed - Clinical trials for Cardiovascular Disease

Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events

Start date: April 2003
Phase: Phase 4
Study type: Interventional

Homocysteine recently gained access to the category of risk factor for the development of atherosclerotic cardiovascular disease in the general population. Chronic renal failure patients, even before being introduced to dialysis therapy have almost universal elevation of serum homocysteine; when on dialysis their mortality is above 50% related to cardiovascular disease that we might now speculate, with a contribution of potentially toxic levels of the aminoacid homocysteine.